International liquid biopsy standardization alliance white paper

Crit Rev Oncol Hematol. 2020 Dec;156:103112. doi: 10.1016/j.critrevonc.2020.103112. Epub 2020 Sep 30.


The promise of precision medicine as a model to customize health care to the individual patient is heavily dependent upon new genetic tools to classify and characterize diseases and their hosts. Liquid biopsies serve as a safe alternative to solid biopsies and are thus a useful and critical component to fully realizing personalized medicine. The International Liquid Biopsy Standardization Alliance (ILSA) comprises organizations and foundations that recognize the importance of working towards the global use of liquid biopsy in oncology practice to support clinical decision making and regulatory considerations and seek to promote it in their communities. This manuscript provides an overview of the independent liquid biopsy- and standardization-based programs engaged with ILSA, their objectives and progress to date, and the tools and resources each is developing to contribute to the field. It also describes the unique areas of effort as well as synergy found within the group.

Keywords: CTCs; Circulating tumor cells; Exosomes; Liquid biopsy; cfDNA.

Publication types

  • Review

MeSH terms

  • Biomarkers, Tumor
  • Biopsy
  • Humans
  • Liquid Biopsy
  • Neoplastic Cells, Circulating*
  • Precision Medicine


  • Biomarkers, Tumor